FDA-cleared Access AMH immunoassay, 3/18

March 2018—Beckman Coulter Diagnostics announced FDA clearance of its automated Access AMH immunoassay for in vitro diagnostic use. This test aids health care providers in the assessment of a woman's ovarian reserve and helps guide the clinical management of women struggling with infertility or planning to become pregnant later in life.

The Access AMH assay is a paramagnetic particle chemiluminescent immunoassay for the quantitative determination of anti-müllerian hormone levels. The test is intended for use in conjunction with other clinical and laboratory findings, such as antral follicle count, before starting fertility therapy.

Beckman Coulter Diagnostics*, 714-993-5321*